WebMay 30, 2024 · May 30 (Reuters) - Protagonist Therapeutics Inc. * Protagonist therapeutics enters into worldwide agreement with janssen to co-develop and commercialize ptg-200 … WebMay 8, 2024 · The expanded agreement builds upon Protagonist's ongoing development collaboration with Janssen on PTG-200 and triggers a $25 million milestone payment to …
Safety and Efficacy Study of PTG-100 in the Treatment of
WebDec 17, 2024 · We remind investors that Protagonist Therapeutics and Janssen Biotech are currently evaluating PTG-200, an oral IL-23 receptor antagonist, in a phase II study for … larcher architecte strasbourg
Safety and Efficacy Study of PTG-100 in the Treatment of …
WebSearch results for refersto:recid:544266. Number of results: 230 ≪ < page 1 of 10 > ≫. Brief list Raw JSON WebMay 30, 2024 · On May 30, 2024 Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced that it has entered into a worldwide exclusive license … WebAug 24, 2024 · * Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment hengrove bristol postcode